REWIND
Researching Cardiovascular Events with a Weekly Incretin in Diabetes
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 9,901 patients with T2DM mostly without established CV disease, dulaglutide 1.5 mg weekly reduced CV death, non-fatal MI or non-fatal stroke compared with placebo.
N
9901
Disegno
Double-blind RCT, median 5.4 yr
Esito
3-point MACE
Rilevanza
2
RisultatoHR 0.88 (p=0.026). Benefit consistent in patients with and without established CVD.
Gerstein HC, et al. Lancet. 2019;394(10193):121-130. 10.1016/S0140-6736(19)31149-3
Discussione e critica
Extended GLP-1 RA benefit into the primary-prevention population — broadened the indication beyond established CVD.